AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: Pulmozyme (Genentech) (pulmozyme.com)
This is a low-BS, highly regulated pharmaceutical site that prioritizes clinical data and technical specifications over marketing fluff. Its only ‘bullshit’ is the repetitive use of high-level marketing slogans in headers to frame the dense medical content. It serves as a benchmark for Substance-First communication in the sector.
Add direct outbound links to the specific peer-reviewed studies mentioned in the Pediatric Use section. Include ClinicalTrials.gov registration numbers for all referenced trials to enhance the proof path. Reduce the visual repetition of the 30+ years slogan to prevent the homepage from feeling like a marketing loop. Implement Person schema for Genentech’s clinical leadership to strengthen technical authority.
The site maintains high information density, especially on the equipment and treatment pages. Specific technical requirements such as ‘pressure and flow rate maximum 30 psi, 12 LPM’ and ‘FVC >= 40% of predicted’ provide substantial substance. However, the H3 and H5 headings ‘Over 30+ years of results and counting’ are repetitive and lean into marketing territory compared to the clinical body text.
If your primary content isn't server side, your site collapses into an empty shell for every LLM. Check your server side content exposure and confirm whether AI can extract anything meaningful at all.
There is zero semantic drift between the homepage and sub-pages. The H1 promise of a ‘multitherapy approach’ is directly substantiated on the treatment page, which details how Pulmozyme interacts with CFTR modulators, bronchodilators, and antibiotics. The transition from high-level management claims to granular equipment lists is logically consistent.
Move beyond vague agency reporting and visualize your surgical implementation plan. Order an Executive SEO Strategy and stop relying on superficial keyword tracking.
The site triggers trust theatre flags due to a review_count of 5 on the equipment page while the proof_links_count is 0. While pharmaceutical sites rely on Prescribing Information (PI) links, the absence of direct links to the mentioned ‘randomized, controlled trial’ or ClinicalTrials.gov identifiers within the text is a minor proof path failure. The presence of reviews without verifiable third-party links is the primary driver here.
The ratio of evidence to assertions is high. For every claim about treatment efficacy, there is a corresponding ‘Indication and Usage’ or ‘Important Safety Information’ block. The site identifies 5 specific vibrating mesh nebulizers and multiple jet nebulizer combinations by brand name, providing a high proof density.
For a high volume editorial domain example, open the Search Engine Journal Semantic HTML audit. View the SEJ Semantic HTML Audit to see how template drift and structural noise impact AI chunking.
The commodity fingerprint is low because the product is a specific molecular entity (dornase alfa) with no direct interchangeable competitors. Cliché usage is limited to standard industry jargon like ‘FDA approved’ and ‘mechanism of action.’ The template language in ‘Quick Links’ and ‘Financial support’ is populated with specific pharmaceutical assistance data rather than generic filler.
Authority is established via Genentech Organization schema and official FDA indication statements. A minor gap exists as no specific clinical leads are named or linked via Person schema, though this is standard for branded drug sites. Technical implementation is clean with a functional heading hierarchy and zero drift.
Performance claims are grounded in clinical indications rather than marketing hyperbole. The claim of ‘Over 30+ years of results’ is a historical fact for this drug approved in 1993, though it lacks a direct citation. There are no bold performance claims that are not immediately qualified by mandatory Safety Information.
Medical Devices, Pharma & Biotech BS: Pulmozyme (Genentech) (pulmozyme.com)
Pulmozyme is a textbook pharmaceutical product site. The content strictly adheres to FDA-regulated communication patterns, focusing on Indication, Usage, and Safety Information (ISI).
A page that loads perfectly for users can still return an empty shell to an AI crawler. Examine the Crawlability Technical Guide and understand why script free extraction is the real measure of visibility.
“The score of 23 is primarily driven by Step 3's Trust Theatre and Step 4's Industry Cliché Density. The lack of direct external proof links for clinical trials and the use of unverified review counts contributed 11 points. Information density deductions were minimal, reflecting the site's high technical specificity.”
Analysis Disclosure & Source Attribution
Snapshot Date: June 19, 2026
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to see how machine logic interprets digital signals.
Machine Perception Notice: This evaluation is generated by machine-read logic (MRL). The AI interprets the “Digital Ghost” of a website (code, metadata, and semantic structures), which may differ from what a human sees at the same moment. This is an automated technical diagnostic and not a statement of fact or human opinion regarding the real-world integrity or legitimacy of the business. Any missing or inaccessible elements in the snapshot are treated as machine-read signals, reflecting AI rendering limitations rather than intentional omission.
Notice to the Evaluated Business: This analysis is part of a non-adversarial audit. The results are intended as professional feedback to help improve machine-readability and authority signals. Any company can use these insights for free. When content is updated, a fresh audit can be requested at any time to reflect the current state.
To All Users: You are encouraged to visit the live site at Pulmozyme (Genentech) to view the most current version of their content and see directly what the company offers.